Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment

BACKGROUND: A wide range of response rates have been reported in HER2-positive gastric cancer (GC) patients treated with trastuzumab. Other HER2-targeted therapies for GC have yet to show efficacy in clinical trials. These findings raise question about the ability of standard HER2 diagnostics to acc...

Descripción completa

Detalles Bibliográficos
Autores principales: An, E., Ock, C.-Y., Kim, T.-Y., Lee, K.-H., Han, S.-W., Im, S.-A., Liao, W.-L., Cecchi, F., Blackler, A., Thyparambil, S., Kim, W. H., Burrows, J., Hembrough, T., Catenacci, D. V. T., Oh, D.-Y., Bang, Y.-J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378223/
https://www.ncbi.nlm.nih.gov/pubmed/27687309
http://dx.doi.org/10.1093/annonc/mdw442

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378223/
https://www.ncbi.nlm.nih.gov/pubmed/27687309
http://dx.doi.org/10.1093/annonc/mdw442

Ejemplares similares